Case Report: Long-Term Follow-Up of Visceral Leishmaniasis and HIV Coinfected Patients Without Relapse: Lymphoproliferative Response After Stimulation with Soluble
Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Begoña Monge-MailloNational Reference Unit for Tropical Diseases, Department of Infectious Diseases, Ramón y Cajal University Hospital, WHO Collaborating Center for Clinical Management of Leishmaniasis, Ramón y Cajal Research Institute (IRYCIS), 28034 Madrid, Spain.
Daniel Roger-ZapataHospital Universitario del Sureste, 28500 Madrid, Spain.
Fernando DrondaCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-0443-5816
Eugenia CarrilloCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-7869-7915
Javier MorenoCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-0087-4659
María Dolores Corbacho-LoarteNational Reference Unit for Tropical Diseases, Department of Infectious Diseases, Ramón y Cajal University Hospital, WHO Collaborating Center for Clinical Management of Leishmaniasis, Ramón y Cajal Research Institute (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0002-1674-6304
Diego Gayoso CanteroNational Reference Unit for Tropical Diseases, Department of Infectious Diseases, Ramón y Cajal University Hospital, WHO Collaborating Center for Clinical Management of Leishmaniasis, Ramón y Cajal Research Institute (IRYCIS), 28034 Madrid, Spain.
Oihane MartínCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Sandra Chamorro-TojeiroNational Reference Unit for Tropical Diseases, Department of Infectious Diseases, Ramón y Cajal University Hospital, WHO Collaborating Center for Clinical Management of Leishmaniasis, Ramón y Cajal Research Institute (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0003-0960-1630
Jose A Perez-MolinaNational Reference Unit for Tropical Diseases, Department of Infectious Diseases, Ramón y Cajal University Hospital, WHO Collaborating Center for Clinical Management of Leishmaniasis, Ramón y Cajal Research Institute (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0001-8735-4124
Francesca NormanNational Reference Unit for Tropical Diseases, Department of Infectious Diseases, Ramón y Cajal University Hospital, WHO Collaborating Center for Clinical Management of Leishmaniasis, Ramón y Cajal Research Institute (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0003-0336-7767
Marta González-SanzNational Reference Unit for Tropical Diseases, Department of Infectious Diseases, Ramón y Cajal University Hospital, WHO Collaborating Center for Clinical Management of Leishmaniasis, Ramón y Cajal Research Institute (IRYCIS), 28034 Madrid, Spain.ORCID 0000-0002-3252-9748
Rogelio López-VélezNational Reference Unit for Tropical Diseases, Department of Infectious Diseases, Ramón y Cajal University Hospital, WHO Collaborating Center for Clinical Management of Leishmaniasis, Ramón y Cajal Research Institute (IRYCIS), 28034 Madrid, Spain.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Highly active antiretroviral therapy (HAART) has reduced the incidence of VL/HIV dramatically. However, HAART only partially prevents relapses, with one-year relapse rates ranging from 30 to 60%. Consequently, secondary prophylaxis is recommended for patients with <200 CD4+ cells/μL. In clinical practice, characterizing cellular immune response could help estimate the risk of relapse in VL/HIV coinfected patients. In this study, the lymphoproliferative response after stimulation with soluble
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Case Report: Long-Term Follow-Up of Visceral Leishmaniasis and HIV Coinfected Patients Without Relapse: Lymphoproliferative Response After Stimulation with Soluble · full record | Socratic